These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22385486)

  • 1. Intravitreal triamcinolone in Coats' disease.
    Ghazi NG; Al Shamsi H; Larsson J; Abboud E
    Ophthalmology; 2012 Mar; 119(3):648-9. PubMed ID: 22385486
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination treatment of pediatric coats' disease: a bicenter study in Taiwan.
    Lin CJ; Chen SN; Hwang JF; Yang CM
    J Pediatr Ophthalmol Strabismus; 2013; 50(6):356-62. PubMed ID: 24669373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma.
    Parrozzani R; Pilotto E; Dario A; Miglionico G; Midena E
    Am J Ophthalmol; 2013 Jan; 155(1):127-133.e2. PubMed ID: 22995029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of total retinal detachment in Coats' disease with intravitreal injection of bevacizumab.
    Zhao T; Wang K; Ma Y; Jiang YR
    Graefes Arch Clin Exp Ophthalmol; 2011 Nov; 249(11):1745-6. PubMed ID: 21080196
    [No Abstract]   [Full Text] [Related]  

  • 5. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
    Ramasubramanian A; Shields CL
    Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome.
    Andrade RE; Muccioli C; Farah ME; Nussenblatt RB; Belfort R
    Am J Ophthalmol; 2004 Mar; 137(3):572-4. PubMed ID: 15013890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema.
    Ozdemir H; Karacorlu M; Karacorlu SA
    Am J Ophthalmol; 2005 Aug; 140(2):251-5. PubMed ID: 15992756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraocular concentrations of cytokines and chemokines in rhegmatogenous retinal detachment and the effect of intravitreal triamcinolone acetonide.
    Kunikata H; Yasuda M; Aizawa N; Tanaka Y; Abe T; Nakazawa T
    Am J Ophthalmol; 2013 Jun; 155(6):1028-1037.e1. PubMed ID: 23490191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Magnetic Resonance Imaging in Unilateral Coats' Disease.
    Verma R; Wilson-Pogmore A; Russell H; Bhuta S
    J Pediatr Ophthalmol Strabismus; 2019 Nov; 56(6):407. PubMed ID: 31743411
    [No Abstract]   [Full Text] [Related]  

  • 11. A 6-year-old boy with Cornelia de Lange syndrome and Coats disease: case report and review of the literature.
    Stacey AW; Sparagna C; Borri M; Rizzo S; Hadjistilianou T
    J AAPOS; 2015 Oct; 19(5):474-8. PubMed ID: 26486036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S; Rush R; Natarajan S; Gillies M
    Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choroidal detachment secondary to intravitreal dexamethasone implant in a patient with Coats' disease.
    Guemes-Villahoz N; Gómez-Calleja V; López-Guajardo L; Donate-López J
    J Fr Ophtalmol; 2021 Oct; 44(8):1306-1307. PubMed ID: 34452764
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of intravitreal triamcinolone acetonide injection in unilateral idiopathic juxtafoveal telangiectasis.
    Li KK; Goh TY; Parsons H; Chan WM; Lam DS
    Clin Exp Ophthalmol; 2005 Oct; 33(5):542-4. PubMed ID: 16181291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal triamcinolone acetonide as treatment for extensive exudative retinal detachment.
    Jonas JB
    Br J Ophthalmol; 2004 Apr; 88(4):587-8. PubMed ID: 15031187
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections.
    Alshareef RA; Garg SJ; Hsu J; Vander J; Park C; Spirn MJ
    J Ocul Pharmacol Ther; 2014 Aug; 30(6):512-6. PubMed ID: 24828198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal triamcinolone acetonide for treatment of serous macular detachment in central retinal vein occlusion.
    Karacorlu M; Karacorlu SA; Ozdemir H; Senturk F
    Retina; 2007 Oct; 27(8):1026-30. PubMed ID: 18040239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications.
    Othman IS; Moussa M; Bouhaimed M
    Br J Ophthalmol; 2010 May; 94(5):606-10. PubMed ID: 19955197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual outcomes after treatment in pediatric patients with Coats' disease.
    Chiu HH; Wan MJ; Kertes PJ; Muni RH; Lam WC
    Can J Ophthalmol; 2019 Dec; 54(6):647-652. PubMed ID: 31836093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
    Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
    Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.